Kite and Shoreline Biosciences Form Strategic Partnership to Develop Novel Allogeneic Cell Therapies

Kite, Shoreline Biosciences | June 18, 2021

Kite, a Gilead Company, and Shoreline Biosciences, Inc., a biotechnology firm developing intelligently designed allogeneic off-the-shelf, standardized, and targeted natural killer (NK) and Macrophage cellular immunotherapies achieved from induced pluripotent stem cells (iPSC) for cancer and other serious diseases, announced a strategic partnership today to develop novel cell therapies across a variety of indications.

The collaboration will combine Shoreline’s profound experience in iPSC differentiation and genetic reprogramming with Kite’s extensive cell therapy development, commercialization, and manufacturing capabilities to develop new allogeneic candidates for a variety of hematologic malignancies. The collaboration will initially focus on chimeric antigen receptor (CAR) NK targets, with Kite having the option to expand the partnership to include an iPSC CAR Macrophage program for an undisclosed target to be picked after the deal is completed. This agreement comes on the back of Kite’s investment in Shoreline’s recent Series A financing.

“As the pioneer in cell therapy, we are focused on investing in and delivering on the most promising possibilities to improve cell therapy’s therapeutic potential further,” said Mert Aktar, Kite’s Vice President of Corporate Development and Strategy. “We are excited about the potential of Shoreline’s next-generation approach to allogeneic development, as well as how our partnership might accelerate this research across various leukemias and lymphomas.”

“Through this strong partnership, we are thrilled to strengthen our relationship with Kite, which is at the forefront of cancer immunotherapy for more than ten years,” said Kleanthis G. Xanthopoulos, Ph.D., Shoreline Co-Founder, Chairman, and CEO. “The combination of Kite’s experience in CAR T-cell therapies with our cutting-edge iPSC platform has the potential to accelerate Shoreline’s timeline to the clinic, expand our pipeline opportunities, and offer transformative cancer treatment options.”

According to the terms of the agreement, Shoreline will get an initial payment and will be eligible for further payments totaling more than $2.3 billion, as well as royalties based on the accomplishment of specific development and commercial milestones.

About Shoreline Biosciences
Shoreline is a biotechnology firm committed to developing intelligently designed allogeneic off-the-shelf, targeted, and standardized cellular immunotherapies for cancer and other severe illnesses. Shoreline is building a pipeline of natural killer (NK) cell and macrophage-cell treatment options based on its extensive knowledge of iPSC differentiation methods and genetic reprogramming of disease-relevant pathways.

About Kite
Kite, a Gilead Company, is a biopharmaceutical company headquartered in Santa Monica, California, with commercial manufacturing facilities in North America and Europe. Kite’s sole focus is on cell therapy to treat and possibly cure cancer. As the pioneer in cell therapy, Kite has more authorized CAR T indications to help more patients than any other company.


Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis. 


Phenylmethylsulfonyl fluoride, better known as PMSF, is a small molecule serine protease inhibitor used to prevent unwanted proteolysis. 

Related News


Benchling Reinforces Security Commitment with Type 2 SOC 2

Benchling | January 27, 2023

On January 27, 2023, Benchling, the R&D cloud that powers the biotechnology sector, announced that it has passed the System and Organization Controls (SOC) 2 certification. Schellman, an independent Certified Public Accounting (CPA) firm, conducted the Type 2 SOC 2 test according to the AICPA's SOC 2 standards. Type 2 SOC 2 evaluates the design and operational performance of an organization's security processes and controls to meet its security goals and customer commitments during a predetermined evaluation period. Constant monitoring, evaluation, and modification of the requirements and security measures guarantee a secure environment for doing business. The CISO at Benchling, Zach Powers, said, "Biotechs are managing an evolving landscape of security and compliance risks, and they require trusted software partners to help them meet these demands." He added, "At Benchling, we make the security, privacy, and compliance of our customers' sensitive data a company-wide, critical investment, not only through Type 2 SOC 2, but also through our best-in-class security team, our trust-but-verify processes, and our adherence to global compliance standards." (Source – PR Newswire) Benchling's R&D Cloud is the biotech R&D platform of choice, trusted by over 1,000 organizations worldwide in highly regulated areas such as biopharmaceuticals, agribusiness, industrials, and consumer packaged goods. Benchling is used by customers to securely store, standardize, and analyze crucial data related to the design and development of innovative biotech products. Benchling's objective is to protect client data; hence, the firm utilizes sophisticated data security and privacy protections and complies with tight regulatory regulations such as the NIST Cybersecurity Framework. The organization is also ISO 27001 certified. The successful completion of Benchling's Type 2 SOC 2 inspection assures that its biotech clients can conduct crucial R&D work in the Benchling R&D Cloud while following the highest security requirements. About Benchling Benchling is a San Francisco-based firm that focuses on private and public life science cooperation by developing cloud-based software tools for digital DNA sequence editing, planning and performing experiments, evaluating data, and sharing research. More than 200,000 scientists from over 1,000 firms and 7,500 university and research institutions worldwide have used the Benchling R&D Cloud to create breakthrough discoveries and deliver the next generation of medicines, foods, and materials to market more quickly. In addition, the R&D cloud assists these companies in modernizing their scientific processes and accelerating their cooperation to transform the complexity of biology into world-changing outcomes.

Read More


Janux Therapeutics Submits IND Application for JANX008

Janux | December 29, 2022

Janux Therapeutics, Inc. is a clinical-stage biopharmaceutical company that uses its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms to develop a diverse pipeline of novel immunotherapies. On December 27, 2022, the company announced that it had submitted an investigational new drug (IND) application for JANX008 to U.S. Food and Drug Administration, an EGFR-TRACTr in (SCCHN). The company is pleased to announce its second IND. It considers this a big step forward for its TRACTr platform, which has also helped many next-generation immunotherapies move forward. JANX008 is made in a particular way to avoid cytokine release syndrome and the known harmful effects of EGFR in on-target healthy tissue. As a result, the company thinks it could be easier to treat EGFR-expressing cancers in many ways. JANX008 is a double-masked TRACTr that conceals both the EGFR-binding and T-cell-specific binding domains (CD3). JANX008 exhibited minor cytokine release syndrome and healthy tissue toxicity in preclinical studies. Besides, it demonstrated superior safety and pharmacokinetic (PK) qualities compared to unmasked TCEs. These data and JANX008's strong manufacturability qualities justify its continued development as a potential therapy for solid tumors. About theJanux Janux Therapeutics is a clinical-stage business developing immunotherapies that target cancers without affecting healthy tissue. The company uses platform masking to generate innovative therapeutic candidates that address T-cell engager toxicity and efficacy limitations. It develops next-generation cancer therapeutics using TRACTR platform. Janux Therapeutics focuses on developing medically-validated T cell engagers (TCEs). Its pipeline includes PSMA, EGFR, and TOP2 efforts. All of its programs are IND-enabling or discovery.

Read More


Be The Match BioTherapies® Introduces CIBMTR® CRO Services

Be The Match BioTherapies® | January 18, 2023

On January 17, 2023, Be The Match BioTherapies, a company that provides solutions for organizations that develop and commercialize cell and gene therapies, introduced its offering of CIBMTR® clinical research organization services (CRO services), which significantly reduces the time needed to launch and execute high-impact clinical trials. These CRO services are the outcome of a collaboration between Be The Match BioTherapies and CIBMTR, resulting in expertise and access to unmatched research, sites, donors, partnerships, scientific and operational knowledge, and other resources. CIBMTR CRO services offer unique capabilities such as Established relationships with over 225 clinical locations domestically Nearly 20 years of expertise in transplant and cellular therapy trials and study management, as well as clinically-trained staff On-staff transplant physicians provide direct contact with patients and donors for clinical and research insights. A link to the CIBMTR outcomes database for over 575,000 patients The new CRO services offer turn-key solutions, including protocol development and approval oversight, site selection, project management, site start-up, research sample/laboratory coordination, data management, study monitoring, patient-reported outcomes, statistical analysis, and financial administration. For certain services, such as data analysis, surveys, site selection and administration, and sample management, businesses may instead rely on the expertise of CIBMTR CRO services. About Be The Match BioTherapies® Be The Match BioTherapies is the sole supplier of cell and gene therapy solutions with fully configurable services to assist the cell therapy supply chain. It is committed to accelerating patient access to life-saving cell and gene treatments by delivering the best-quality cellular source material from Be The Match Registry®, the most-varied registry of prospective blood stem cell donors in the world, with over 7 million potential blood stem cell donors. Through global collaborations with apheresis, bone marrow collection, and transplant centers, the firm creates, onboards, trains, and maintains extensive collection networks to advance cell treatments.

Read More